Canaccord lowered the firm’s price target on Pliant Therapeutics (PLRX) to $3 from $4 and keeps a Hold rating on the shares. The firm said Pliant reported financial results and business highlights for 4Q25 and FY2025. As of December 31, 2025, the company had cash and cash equivalents of $192.4M. Management believes that the cash on hand is sufficient to fund planned operations into 2H28.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance
- Pliant Therapeutics price target lowered to $3 from $4 at Piper Sandler
- Pliant Therapeutics reports Q4 EPS (38c), consensus (38c)
- Pliant Therapeutics Extends Stockholder Rights Agreement Expiration
- PLRX Earnings this Week: How Will it Perform?